Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO)
Published inAnnals of oncology, vol. 11, no. 3, p. 301-306
Publication date2000
Abstract
Keywords
- Adenocarcinoma/drug therapy/mortality/secondary
- Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
- Cisplatin/administration & dosage/adverse effects
- Humans
- Paclitaxel/administration & dosage/adverse effects/analogs & derivatives
- Stomach Neoplasms/drug therapy/mortality/pathology
- Survival Analysis
- Taxoids
NoteOpen Access - Licence nationale Oxford University Press
Research group
Citation (ISO format)
ROTH, Arnaud et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). In: Annals of oncology, 2000, vol. 11, n° 3, p. 301–306. doi: 10.1023/A:1008342013224
Main files (1)
Article (Published version)
Identifiers
- PID : unige:55288
- DOI : 10.1023/A:1008342013224
- PMID : 10811496
Commercial URLhttp://annonc.oxfordjournals.org/content/11/3/301.long
ISSN of the journal0923-7534